As the data collection methods have extreme influence over the validity of the research outcomes, it is considered as the crucial aspect of the studies
May 2025 | Source: News-Medical
Real-World Evidence (RWE) is the set of all information gathered from day-to-day clinical practice via various methods, including electronic health records (EHRs), insurance claims, registries, and other forms of documentation. Through our pharma analytics, RWE analytics, and pharmaceutical research data analysis offerings within the pharmaceutical industry, we support organizations in utilizing that information in a constructive manner so that manufacturers can make informed choices about drug development, which leads to better treatment options for patients and maximized profitability for manufacturers. Our data analysis services in UK enable pharmaceutical companies to process and interpret these datasets efficiently .[1]
Sources for RWE (real-world evidence) Are:
Clinical trials measure the potential effect of a service in a controlled research environment, whereas RWE collects live data of patients under care for the same disease(s).
By using both RWE and clinical trial data as a combined resource, pharmaceutical manufacturers will be able to determine:
Aspect | Short Description | Examples |
Advanced Analytics | Derives important information out of RWD. | Determine optimal drug dosage based on patient data. |
Healthcare Analytics | Identifies trends and patterns within RWD. | Adverse Events Dashboard tracking RWD adverse events. |
Predictive Modeling | Predicting patient outcomes and treatment responses. | Predict patients with high risk for readmission.[2] |
Data-driven strategies and Improved Patient Outcomes via A Pharma Research Data/RWE Analytics.
RWE is an important source of information. However, there are challenges associated with inconsistent data quality, difficulty integrating many different types of data, and complying with various privacy regulations. To obtain reliable evidence from pharmaceutical data, a strong healthcare analytics approach to engaged clinical data is critical, offered by leading data analytics companies UK.
Aspect | Aspect of Extensive Data Use |
2025 Pharma | Focus Growing dependence on data analysis, real-world evidence analytics, and AI-enabled solutions as competition increases. |
Emerging Trend 1 | Predictive Modeling for Patient Outcome Forecasting |
Emerging Trend 2 | AI-Powered Trial Simulations Enhance Study Design and Cost Reduction [4] |
Emerging Trend 3 | Real-Time Monitoring to Support Immediate and Accurate Decision Making |
Advantage | Adoption of These Technologies Today Provides Immediate Insight, Increase Efficiency in Drug Development, and Better Market Performance.[5] |
Example – A pharma company uses AI-driven RWE analytics to predict patient outcomes, run virtual trial simulations, and monitor real-time safety data—leading to faster decisions and more efficient drug development.
Category | Description | Metric |
Data Digitization | data digitised and collected from machines for AI analysis | 90% manual entry has been replaced |
Optimizing Machinery | improving the efficiency of equipment by utilising AI | 25% increase in equipment uptime |
Machine Failure Analysis | ai can detect machine failure patterns and trends to help prevent downtime [3] | 30% decrease in unscheduled downtime |
Smarter Procurement Guidance | AI provides guidance on purchasing and inventory decisions | 15% decrease in procurement costs |
Increased Operational Efficiency | AI helps streamline operational processes and make good decisions – | 20% increase in operational efficiency |
By 2025, strong data analysis will be required if pharmaceutical (pharma) companies intend to be competitive with their competition. Each of these will have RWE analytics, Pharma analytics and their use of artificial intelligence (AI) to be able to derive insights from data.[5] Using strong, quality pharmaceutical research data and the latest healthcare analytics would allow these companies to develop drugs effectively, support regulatory compliance and make quicker and smarter decisions. Advanced use of clinical data analysis and Drug Development analytics will lead to improved results with lower risk and prepare these companies for the continued evolution of the pharmaceutical industry.
Call to Action (CTA)
Unlock the full potential of your pharma data with Statswork.
From RWE analytics to clinical data interpretation, our expert-driven data analysis solutions help you make confident, faster, and more impactful decisions.
